Filing Flows

Filing Flows › Anika Therapeutics (ANIK) › Next earnings date

Anika Therapeutics (ANIK) earnings: beat the estimate

Anika Therapeutics (ANIK) reported on Nov 6, 2026 and beat the EPS estimate: $0.29 against $0.17 (+70.6%). Revenue was $30.6M for Q3 2026, +10% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+70.6% vs estimate
Beat rate100%

The last report

Anika Therapeutics reported revenue of $30.6M for the third quarter 2026 (+10% Y/Y), net loss $311K: OEM Channel $16.6M, Commercial Channel $14.0M. How it makes money → · Every quarter →

Anika Therapeutics: EPS against the estimate, last 5 reportsAnika Therapeutics: EPS against the estimate, last 5 reportsEstimateReported$0.02$0.04Nov 25$0.02$0.31Feb 26$0.00$0.27Apr 26$0.03$0.42Jul 26$0.17$0.29Nov 26
Latest (Nov 26): Estimate $0.17, Reported $0.29.

Anika Therapeutics' latest quarter

Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Anika Therapeutics beat earnings?

Anika Therapeutics (ANIK) reported on Nov 6, 2026 and beat the EPS estimate: $0.29 against $0.17 (+70.6%).

When does ANIK report earnings?

The next date is not set yet.

Does Anika Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.